Fluoroquinolone antibiotic. Inhibits bacterial DNA topoisomerase IV and DNA gyrase and forms a stable quinolone-DNA complex with these enzymes which reversibly inhibits DNA synthesis. Displays potent activity against gram-positive and gram-negative bacteria. Increases the production of mitochondrial NO in immortalized hepatocytes; also increases mitochondrial Ca2+
. Inhibits Panx-1 (IC50
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
Unexpected link between an antibiotic, pannexin channels and apoptosis.
Poon et al.
In vitro activity of the new fluoroquinolone CP-99,219.
Neu and Chin
Antimicrob.Agents Chemother., 1994;38:2615
Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
Gootz et al.
Antimicrob.Agents Chemother., 1996;40:2691